Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
> Improved financials
Launch excellence
High-value innovation
Operational excellence
Strengthen foundations
Conclusion
Abbreviations
-
Continuing to deliver improved financials – sales,
core margin, free cash flow and return on invested capital
New-Novartis expectations (illustrative only)
Sales
% CC, CAGR
+4%
Incremental benefit
from Sandoz spin-off
Free Cash Flow
% of sales
2021
2027
Core Operating Income Margin
(corporate costs absorbed)
2021
2027
Return on Invested Capital
~40%+
2021
2027+
2021
2027
17
Novartis Investor Presentation | September 22, 2022
1. Improved financials
> IM expected to grow sales, margin and
FCF (% of sales)
> Margin targets includes absorbing
corporate costs
Sandoz spin-off will result in
incremental growth for:
-
-
Core operating income margin
FCF (% of sales)
- Return on invested capital
> New-Novartis remains committed
to capital allocation priorities,
with growing (CHF) annual dividend
U |
NOVARTIS | Reimagining MedicineView entire presentation